We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

PerkinElmer Collaborates on Preterm Birth Biomarkers

By HospiMedica staff writers
Posted on 21 Aug 2006
PerkinElmer, Inc. (Wellesley, MA, USA) has announced a multi-year license-and-research agreement with the University of Leicester (Leicester, United Kingdom) under which the two organizations will begin to lay the groundwork for the clinical investigation and discovery of biomarkers that predict preterm birth (PTB). The collaboration will be financed by PerkinElmer.

PerkinElmer will support the expansion of the University of Leicester's maternal health research capabilities and provide advanced tools, technology, and expertise. Professor J. C. Konje, M.D., and colleagues of Leicester University's reproductive sciences section of the department of cancer studies and molecular medicine are dedicated to the study and prediction of preterm birth. The team is conducting research in the field of preterm labor diagnosis.

The partnership will give PerkinElmer broader access within Professor Konje's research group to clinical samples, methodology, and clinical consultancy support in the field of maternal health. The University of Leicester and PerkinElmer will work towards validating any new PTB biomarkers that will complement PerkinElmer's maternal health portfolio. PerkinElmer and the University of Leicester will share access to licensed intellectual property from new PTB biomarkers that result from this research.

It is estimated that preterm labor complicates 6-10% of all pregnancies and is the most common cause of neonatal morbidity and mortality. Worldwide statistics reflect that there may be as many as 13 million preterm births annually, and this figure is predicted to increase. In the United States alone, an estimated U.S.$820 million is spent on preterm hospitalization subsequently shown to have been unnecessary. These hospitalizations tax both the mother's health and healthcare resources.

Currently, there are no rapid or accurate tests that positively predict preterm labor. The aim of the collaboration between PerkinElmer and the University of Leicester is to effectively address this need and eventually design and supply an effective preterm labor test predictor.



Related Links:
PerkinElmer
University of Leicester

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Gold Member
X-Ray QA Meter
T3 AD Pro
New
Ultrasonic Cleaner
Cole-Parmer Ultrasonic Cleaner with Digital Timer
New
Documentation System For Blood Banks
HettInfo II

Latest Business News

Boston Scientific Acquires Medical Device Company Intera Oncology

MEDICA 2024 to Highlight Hot Topics of MedTech Industry

Start-Ups To Once Again Play Starring Role at MEDICA 2024